Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease

The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.

Subsidie
€ 2.992.203
2022

Projectdetails

Introduction

A major challenge facing Europe is its ageing population and associated increase in diagnosed cases of neurodegenerative diseases (NDD). Parkinson’s disease (PD) is associated with tremor and loss of motor functions due to progressive degeneration of dopaminergic neurons in the brain.

Impact of Parkinson's Disease

This can lead to memory loss and dementia, which is associated with short- and long-term injuries and disabilities with emotional, financial, and social burdens for patients, families, and society. The exact causes and mechanisms underlying PD are still unknown, and existing treatments focus on alleviating symptoms and increasing quality of life, but do not halt or reverse disease progression.

Limitations of Current Research

Although animal models give unique possibilities to study physiological and behavioural mechanisms, drug development fails due to lack of translation to humans. Alternative non-animal NDD models are needed both in terms of better translation and to replace expensive and problematic animal experiments.

New Approach: Connectoids

We will move disease modelling to a new level and replace animal models by creating a new concept we call connectoids. We will develop an ex-vivo-type in vitro human opto-electronic multi-regional brain-organoid disease model in which connectoids are formed by precise spatial arrangement of brain organoids connected via hydrogel tracts that promote axonal pathfinding, functional connection, and signalling.

Technological Innovations

By developing:

  1. Light controllable sub-type specific neurons within regionalized brain organoids, and
  2. Electrodes and waveguides that can penetrate the organoids able to monitor neurotransmitter signalling inside and between the organoids,

we will for the first time be able to sense how a particular brain region responds to a certain therapy and watch in real time how signals are transmitted to other brain regions.

Conclusion

Our model will not only have health benefits, but will relieve a heavy economic burden on society and open up new possibilities for technological and economic development.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.992.203
Totale projectbegroting€ 2.992.203

Tijdlijn

Startdatum1-11-2022
Einddatum31-10-2025
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • DANMARKS TEKNISKE UNIVERSITETpenvoerder
  • LUNDS UNIVERSITET
  • UNIVERSIDAD AUTONOMA DE MADRID
  • BICO GROUP AB
  • CELLINK BIOPRINTING AB

Land(en)

DenmarkSwedenSpain

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Revolutionary high-resolution human 3D brain organoid platform integrating AI-based analytics

The 3D-BrAIn project aims to develop a personalized bio-digital twin of the human brain using advanced organoid cultures and machine learning to enhance precision medicine for CNS disorders.

€ 1.998.347

Vergelijkbare projecten uit andere regelingen

ERC Advanced...

Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotency

The project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies.

€ 2.500.000
ERC Starting...

Engineering human cortical brain organoid’s connections to restore brain functions

This project aims to restore functional neuronal networks in cortical brain lesions using 3D bioprinted human-specific hydrogels and cortical brain organoids for innovative therapeutic solutions.

€ 1.500.000
ERC Consolid...

Bidirectional Brain/Neural-Computer Interaction for Restoration of Mental Health

This project aims to develop a portable neuromodulation system using quantum sensors and magnetic stimulation to precisely target brain oscillations for treating mental health disorders.

€ 1.999.875
ERC Proof of...

An automated platform for the large-scale production of miniaturized neuromuscular organoids

The project aims to automate and scale the production of complex neuromuscular organoids for high-throughput drug screening to advance therapies for neuromuscular diseases.

€ 150.000
ERC Proof of...

Human skeletal muscle platform for disease modelling and high-throughput drug screening

Developing a high-throughput in vitro platform with biomimetic skeletal muscle analogues to model neuromuscular disorders for effective drug screening and therapy validation.

€ 150.000